• Recruiting

NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)

Updated: May 26

RRMM


NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)


WVT078

A Study of WVT078 in Patients With Multiple Myeloma (MM)


The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)


Sponsor

Novartis Pharmaceuticals


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04123418


Official Title: A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma


First Posted : October 10, 2019


Click here to see details on ClinicalTrials.gov

 

Biological: WVT078

Anti-BCMA/Anti-CD3 Bispecific Antibody WVT078

Anti-BCMA/CD3 Bispecific Antibody WVT078

BCMA x CD3 Bispecific Antibody WVT078

WVT 078

WVT-078

WVT078


Drug: WHG626

 

Locations

United States, Georgia

United States, Minnesota

United States, Wisconsin

Australia, Victoria

Europe

Germany

Italy

Spain

Norway

Asia

Israel

Japan


Posts Archive